Technical Analysis for THAR - Tharimmune, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | -2.27% | |
| Oversold Stochastic | Weakness | -2.27% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 6.81% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 6.81% | |
| MACD Bullish Signal Line Cross | Bullish | 6.81% | |
| NR7 | Range Contraction | 6.81% | |
| Narrow Range Bar | Range Contraction | 6.81% |
| Alert | Time |
|---|---|
| Down 3% | about 7 hours ago |
| Down 2 % | about 7 hours ago |
| Down 1% | about 7 hours ago |
| Rose Above Previous Day's High | 3 days ago |
| 2x Volume Pace | 3 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors. Tharimmune has a license agreement with OmniAb, Inc. to access the company's antibody discovery technology platform against specified targets.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Immunology Solid Tumors Autoimmune Disease Antibodies Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Immunology Solid Tumors Autoimmune Disease Antibodies Oncology Cancer Immunotherapy Antibody Hepatology Inflammatory Primary Biliary Cholangitis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 163.0875 |
| 52 Week Low | 2.75 |
| Average Volume | 51,555 |
| 200-Day Moving Average | 23.24 |
| 50-Day Moving Average | 4.72 |
| 20-Day Moving Average | 3.69 |
| 10-Day Moving Average | 3.15 |
| Average True Range | 0.43 |
| RSI (14) | 44.13 |
| ADX | 29.7 |
| +DI | 21.89 |
| -DI | 26.75 |
| Chandelier Exit (Long, 3 ATRs) | 4.19 |
| Chandelier Exit (Short, 3 ATRs) | 4.04 |
| Upper Bollinger Bands | 5.39 |
| Lower Bollinger Band | 1.99 |
| Percent B (%b) | 0.43 |
| BandWidth | 92.02 |
| MACD Line | -0.46 |
| MACD Signal Line | -0.54 |
| MACD Histogram | 0.0736 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.76 | ||||
| Resistance 3 (R3) | 3.77 | 3.68 | 3.71 | ||
| Resistance 2 (R2) | 3.68 | 3.60 | 3.67 | 3.69 | |
| Resistance 1 (R1) | 3.56 | 3.55 | 3.52 | 3.55 | 3.67 |
| Pivot Point | 3.47 | 3.47 | 3.45 | 3.47 | 3.47 |
| Support 1 (S1) | 3.36 | 3.39 | 3.31 | 3.35 | 3.23 |
| Support 2 (S2) | 3.27 | 3.34 | 3.26 | 3.21 | |
| Support 3 (S3) | 3.15 | 3.27 | 3.19 | ||
| Support 4 (S4) | 3.14 |
